Summary of Microchip (NasdaqGS:MCHP) FY Conference Call - November 18, 2025 Company Overview - **Company**: Microchip Technology Inc. - **Industry**: Semiconductor Key Points Demand Environment - Healthy bookings activity observed over the last several months, with July bookings being the highest in three years [10] - Bookings in September quarter grew by 10% compared to June quarter, with a book-to-bill ratio of 1.06 [12] - Current quarter guidance is slightly below expectations, with a forecasted revenue decline of 1% at the midpoint [11] - November bookings have remained strong, continuing the positive trend [13] Order Dynamics - Aging of bookings is noted, with orders translating into turns orders being lower than expected [11] - No significant push-outs of orders; instead, there is a trend of pull-in activity from customers [15] - Short lead times for products are maintained, with a backlog building into the March quarter [16] Production and Capacity Management - Underutilization charges were approximately $50 million last quarter, expected to decrease as production ramps up [22] - Inventory levels are high at 199 days, with a target of 130 to 150 days [21] - Gradual ramp-up of factory capacity is planned, with a focus on reducing inventory levels [41] Aerospace and Defense Sector - Aerospace and defense business has been steady, benefiting from high US defense budgets and NATO spending [24] - Microchip is the largest supplier of semiconductors to the Department of Defense, with growth opportunities in this sector [25] Data Center Opportunities - Microchip is expanding its presence in the data center market with a full-stack solution [28] - Introduction of a new Gen 6 product on a 3-nanometer process, expected to enhance power efficiency [29] - Data center business historically accounts for 15-20% of total revenue, with potential for growth [30] Gross Margin and Pricing Strategy - Gross margin is expected to improve from 56.7% to 58.2% at the midpoint of guidance for the December quarter [35] - Pricing is stable, with competitive pricing strategies for new designs [34] - Long-term target for gross margin is 60%, with expectations to reach this as early as the March quarter [36] Financial Health and Capital Allocation - Free cash flow is expected to cover dividends, with plans to pay down debt accumulated from previous dividend payments [46] - Current leverage is above desired levels, with a target of 1.5 times net debt to EBITDA [47] - Cash levels are low, with about $250 million on the balance sheet, and focus on debt reduction before considering dividend increases [48] Competitive Dynamics in China - Approximately 18% of revenue comes from China, with half attributed to multinationals and the other half to domestic consumption [50] - Microchip faces competition from local suppliers, particularly in standard microcontroller and analog products [54] FPGA Business Growth - The FPGA business, acquired through MicroSemi, is expanding into new markets beyond aerospace and defense [61] - High margins and growth opportunities are anticipated in the FPGA sector [62] Investor Communication - Emphasis on improving operating margins to reach a target of 40%, with current guidance at 25.7% [63] - Microchip is evolving beyond traditional microcontroller and analog markets, with significant growth opportunities in advanced technologies [64] Conclusion - Microchip is positioned for growth with strong demand in various sectors, effective management of production capacity, and a focus on improving financial health and margins. The company is committed to educating investors about its evolving business model and growth opportunities in advanced semiconductor technologies.

Financial Data and Key Metrics Changes - The company reported a net income of $1.8 million for the nine months ended September 30, 2025, compared to a net loss of $2.7 million for the same period in 2024, marking a $4.5 million improvement [13] - Basic net income per share was approximately $0.20 for the nine-month period ended September 30, 2025, compared to a net loss of $0.34 per share in the prior year [16] - Gross margin as a percentage of product sales increased to 43% during the third quarter of 2025, up from 26% in the same quarter of 2024 [18] Business Line Data and Key Metrics Changes - Total product sales decreased by 8% or $505,000 in the third quarter of 2025 compared to the third quarter of 2024 [16] - Domestic sales increased by 2% in the third quarter of 2025 compared to the same quarter in 2024, and were up 9.5% compared to the second quarter of 2025 [12] - International sales were down during the third quarter of 2025 compared to the same period in 2024, primarily due to timing of shipments and short supply management [12] Market Data and Key Metrics Changes - The U.S. market represented approximately 86% of total sales during the trailing 12-month period ended September 30, 2025 [12] - International sales for the nine-month period ended September 30, 2025, were 15% higher than the same period in the prior year [13] Company Strategy and Development Direction - The company aims to regain customers and expand the use of scour preventatives while exploring new market opportunities more aggressively [11] - The focus is on operational excellence and execution, with a priority on production capacity and quality [14] - The company is awaiting FDA approval for its Retain product, which targets subclinical mastitis, and is conducting investigational product use studies to gather market feedback [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position and the positive changes in the commercial team, emphasizing a shift from managing short supply to winning new customers [26] - The company is focused on maintaining strong production yields and driving growth from existing products while managing cash and inventory effectively [20][31] Other Important Information - The company has undergone significant management transitions, with Oliver Tebukurst appointed as the new President and CEO effective November 1, 2025 [6] - The company has improved its cash position to $3.9 million as of September 30, 2025, from $3.8 million at the end of 2024, while investing in inventory [20] Q&A Session Summary Question: What has changed regarding First Defense and the growth expectations? - Management indicated that they have reached a level of capacity set during the expansion project and have implemented quality measures to ensure predictable manufacturing levels [26] Question: How does the company plan to balance production with cash generation? - The CFO noted that inventory levels have increased to a more desirable level as they approach peak selling season, and they are closely monitoring inventory management [31] Question: What attributed to the margin improvement in Q3? - The CFO attributed the gross margin improvement to enhanced manufacturing performance and a composite price increase of around 6% in 2025 [34]

Summary of Artivion Conference Call Company Overview - **Company**: Artivion - **Industry**: Medical Devices, specifically focusing on aortic technologies Key Points and Arguments Strategic Focus and Vision - Artivion has shifted its focus to cardiac and vascular surgeons treating the aorta, divesting non-aortic products to concentrate on unmet clinical needs in this area [2][3][5] - The company has made several strategic acquisitions over the past five years, including On-X, Jotec, and Ascyrus, to enhance its product offerings and address significant clinical challenges [3][5][6] Product Pipeline and Growth - Artivion has a robust pipeline with seven PMAs (Premarket Approvals) in progress, indicating a strong future growth trajectory without the immediate need for further acquisitions [9][10] - The company anticipates double-digit revenue growth and EBITDA growth at twice the rate of revenue for many years, with recent quarters showing even higher growth rates [15][17][40] AMDS Technology - The AMDS (Aortic Malperfusion Device System) is expected to expand the market for treating acute type A aortic dissections, potentially reducing mortality rates significantly [18][20] - AMDS is positioned to be used in a wider range of centers, which could lead to increased adoption and market expansion [18][20][21] Competitive Landscape - AMDS competes with existing technologies like the Frozen Elephant Trunk and hemianchor repair, but its ease of use and effectiveness may lead to broader adoption among surgeons [21][23] - The company aims to maintain a comprehensive aortic strategy by offering multiple treatment options, ensuring they meet diverse patient needs [23][24] Financial Performance and Projections - The mechanical heart valve business, particularly On-X, has seen significant growth, with recent quarters showing over 20% growth, driven by new clinical data demonstrating advantages over bioprosthetic valves [28][30][31] - The company expects gross margins to improve, with a target of reaching 70% in the long term, driven by the introduction of high-margin products [42][45] Operational and Financial Management - Artivion is focused on maintaining operational scalability to support growth, ensuring that infrastructure keeps pace with increasing demand for high-margin products [49][50] - The company has a solid cash flow management strategy, with priorities including funding for potential acquisitions and debt repayment [57] Market Dynamics and Reimbursement - The introduction of a new DRG (Diagnosis-Related Group) for complex aortic arch procedures is expected to facilitate AMDS adoption by improving reimbursement rates [27] - The company has successfully navigated previous reimbursement challenges, and the new DRG is seen as a positive development for market entry [27] Future Outlook - Artivion is optimistic about its growth prospects, with plans to train surgeons on AMDS and leverage new clinical data to drive market share [33][36] - The company is committed to a long-term growth strategy, focusing on innovation and customer needs in the aortic space [60][61] Additional Important Insights - The company has experienced a significant shift in its market positioning and is now seen as a leader in aortic technologies, with a clear focus on addressing critical clinical needs [1][2][60] - Artivion's management emphasizes the importance of aligning all teams towards a common goal of delivering innovative aortic solutions to improve patient outcomes [60][61]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $118.8 million, a slight increase from $118.6 million in the previous year, marking an important inflection point after consecutive declines [4][16] - Adjusted EBITDA for the quarter was a gain of $200,000, an improvement from a loss of $6.4 million in the prior year, driven by gross margin expansion and disciplined cost management [19] - Gross margin improved to approximately 42.8% from 29.7% in the prior year, reflecting direct material cost savings and improved operational efficiencies [17][19] Business Line Data and Key Metrics Changes - Direct-to-consumer net revenue was $67.2 million, down 5.1% year-over-year, with showroom revenue increasing by 6.5% to $22 million despite fewer stores [16][17] - Wholesale revenue grew by 7.9% to $51.5 million, driven by the Rejuvenate 2.0 launch and expansion with Mattress Firm [17][20] - E-commerce revenue decreased by 9.8% but showed signs of improvement following a website refresh [10][17] Market Data and Key Metrics Changes - The company is on track to reach 12,000 slots in Mattress Firm by March 2026, representing approximately $20 million in incremental revenue this year and an anticipated $70 million next year [11][20] - The overall market appears to be stabilizing, with expectations of flattish results in the category, indicating a potential bottoming out [22][24] Company Strategy and Development Direction - The company is focused on innovation, marketing, and strategic partnerships, with a strong emphasis on the Rejuvenate 2.0 product line and expanding retail partnerships [7][12] - The restructuring program initiated in August 2024 has led to reduced fixed costs and improved operational efficiency, with expected annual savings of $25-$30 million [6][20] - The company aims to maintain gross margins above 40% while continuing to invest in showroom expansion and innovation [14][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning for future growth, despite acknowledging challenges in the broader market [7][24] - The company reiterated its full-year guidance, expecting revenue between $465 million and $485 million and adjusted EBITDA between break-even and $10 million positive [14][20] Other Important Information - The company is engaged in ongoing discussions regarding strategic alternatives, including potential mergers or sales, but will not comment further during the call [15] - Cash and cash equivalents at the end of September were $32.4 million, up from $29 million at the end of 2024, indicating improved liquidity [19][20] Q&A Session Summary Question: What are the encouraging signs in the industry overall? - Management noted that while the market showed signs of improvement around Labor Day, the latter part of September was mixed and soft, but they are encouraged by the performance in October [22][24] Question: Can you discuss margin opportunities for 2026? - Management indicated that gross margins are expected to remain around 40%, with efficiencies from restructuring efforts contributing positively [25][31] Question: How much of the improvement in wholesale was driven by Mattress Firm slots? - The Mattress Firm launch initially hurt productivity due to increased slots, but overall productivity has held steady, which is encouraging [36] Question: What is the long-term e-commerce opportunity for Purple? - Management remains bullish on e-commerce, noting improvements following a website refresh and ongoing efforts to enhance the channel's performance [33] Question: How is showroom profitability trending? - 76% of showrooms were profitable in Q3, up from 56% the previous year, indicating positive progress in this channel [34]

Financial Data and Key Metrics Changes - The company reported Q3 2025 revenues of $202.7 million, with non-GAAP gross margins at 41%, up 250 basis points from 38.5% in Q2 2025 [23][24] - GAAP gross margins for Q3 were 39.8%, compared to 37.3% in Q2 [25] - Non-GAAP EPS for Q3 was $0.33, exceeding the high end of the outlook range of $0.21 to $0.29 [24][30] - Free cash flow in Q3 was $19.7 million, a significant improvement from negative $47.1 million in Q2 [26] Business Line Data and Key Metrics Changes - In the DRAM Probecards segment, there was double-digit sequential growth in Q3, primarily driven by HBM [10] - The systems segment also saw a sequential revenue increase in Q3, with expectations for further growth in Q4 [15] Market Data and Key Metrics Changes - The company expects continued growth in HBM revenue, with Q4 HBM revenue anticipated to be similar to Q3 levels [10] - Demand in the foundry and logic probecard market was weaker in Q3, with expectations of similar demand levels in Q4 [12] Company Strategy and Development Direction - The company is focused on improving profitability to achieve a target model of 47% non-GAAP gross margins [6][19] - Initiatives include rapid gross margin improvement actions and long-term structural initiatives, such as developing differentiated new products and ramping up the new Farmers Branch facility [8][17] - The company aims to expand its market share in advanced packaging and high-performance compute sectors [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving sequentially higher revenue and gross margins in Q4, building on Q3 performance [6] - The company is addressing challenges such as tariffs and supply chain disruptions while focusing on operational efficiency [19][28] Other Important Information - The company plans to invest between $140 million and $170 million in the Farmers Branch facility over 2026, which is expected to improve gross margins beyond the current target model [27][63] - The company has initiated a share repurchase program to offset dilution from stock-based compensation [27] Q&A Session Summary Question: Insights on HBM growth and Probecard intensity - Management noted that the transition to HBM4 is expected to increase test intensity and complexity, driving growth in Probecard demand [34] Question: Contribution of tactical versus structural improvements to gross margin - Management indicated that both tactical and structural improvements are contributing to the gross margin roadmap, with ongoing benefits expected from restructuring actions [36][38] Question: Impact of CPU and GPU customer ramps on foundry and logic - Management acknowledged the potential for significant revenue impact from CPU and GPU customer ramps, although quantification is challenging at this stage [42][43] Question: Revenue growth drivers in Q4 - Management clarified that revenue growth in Q4 is expected to be driven by a mix of legacy DRAM and improvements in operational efficiency [46][47] Question: Timing of capacity increase from Farmers Branch facility - Management expects initial capacity from the Farmers Branch facility to come online late in 2026, with the majority in 2027 [48] Question: HBM revenue specifics for Q3 - Management confirmed that HBM revenue for Q3 was approximately $40 million, with expectations for growth in Q4 driven by HBM4 [53] Question: Status of CPU customer revenue - Management acknowledged that a major CPU customer did not contribute significantly in Q3 but emphasized the importance of the long-term partnership [56] Question: ASIC projects contribution and updates - Management highlighted ongoing engagements with major hyperscalers in the custom ASIC space, with some revenue contribution in Q3 [60]

Financial Data and Key Metrics Changes - The company reported Q3 2025 revenues of $202.7 million, with non-GAAP gross margins at 41%, up 250 basis points from 38.5% in Q2 2025 [23][24] - GAAP gross margins for Q3 were 39.8%, compared to 37.3% in Q2 [25] - Non-GAAP EPS for Q3 was $0.33, exceeding the high end of the outlook range of $0.21-$0.29 [23][24] - Free cash flow in Q3 was $19.7 million, a significant improvement from negative $47.1 million in Q2 [26] Business Line Data and Key Metrics Changes - In the DRAM probecards segment, there was double-digit sequential growth in Q3, primarily driven by HBM [10] - The systems segment also saw a sequential revenue increase in Q3, with expectations for further growth in Q4 [15] Market Data and Key Metrics Changes - The company expects continued growth in HBM revenue, with Q3 HBM revenue around $40 million, primarily from HBM applications [54] - The foundry and logic probecard market experienced weaker demand in Q3, with expectations for similar levels in Q4 [12] Company Strategy and Development Direction - The company is focused on improving profitability to reach a target model of 47% non-GAAP gross margins, with short-term and long-term initiatives in place [6][19] - The strategy includes optimizing operational effectiveness, reducing manufacturing costs, and expanding capacity at a lower cost through the new Farmers Branch facility [8][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving sequentially higher revenue and gross margins in Q4, driven by improved product mix and cost reduction initiatives [6][28] - The company is addressing challenges such as tariffs and supply chain disruptions while focusing on long-term growth opportunities in advanced packaging and high-performance computing [9][28] Other Important Information - The company plans to invest between $140 million and $170 million in the Farmers Branch facility over 2026, which is expected to enhance gross margins beyond the current target model [27][64] - The company is committed to share repurchase programs to offset dilution from stock-based compensation, with $70.9 million remaining for future purchases [27] Q&A Session Summary Question: Insights on HBM growth and test intensity - Management noted that the transition to HBM4 is expected to increase test intensity and complexity, driving demand for probecards [34] Question: Contribution of tactical versus structural improvements to gross margin - Management indicated that both tactical and structural improvements are contributing to the gross margin roadmap, with ongoing benefits expected [37] Question: Impact of CPU and GPU customer ramps on foundry and logic - Management highlighted that while specific quantification is challenging, significant impacts are anticipated as qualifications and commercial negotiations progress [43] Question: Revenue contribution from ASIC projects - Management confirmed ongoing engagement with major hyperscalers in the custom ASIC space, with contributions expected to grow as specifications align with GPU requirements [61] Question: Timing and focus of capacity expansion at Farmers Branch - Management stated that initial capacity from the Farmers Branch facility is expected to come online late in 2026, with a focus on flexibility to support various product lines [49][50]

Core Insights - Ulta Beauty, Inc. reported a significant improvement in profitability metrics for Q2 of fiscal 2025, with gross margin increasing by 90 basis points to 39.2% from 38.3% year-over-year [1][9] - The increase in gross margin was primarily driven by reduced inventory shrink and stronger merchandise margins, although it was partially offset by supply-chain fixed cost deleverage and lower other revenues [1][2] Financial Performance - Gross profit for Q2 rose by 11.6% to $1.1 billion, while selling, general and administrative (SG&A) expenses increased by 15% to $741.7 million from $644.8 million in the prior-year quarter [4] - SG&A expenses as a percentage of net sales increased to 26.6% from 25.3%, attributed to higher incentive compensation, store payroll, benefits, and corporate overhead [4] Management Commentary - Management attributed the margin improvement to disciplined inventory control and refined promotional strategies, with shrink reduction observed across all categories and regions [2][3] - The company anticipates potential margin pressure for the full year due to occupancy and supply-chain costs, although continued improvements in shrink may help mitigate some of this pressure [5][9] Market Performance - Ulta Beauty's shares have increased by 18.8% over the past three months, outperforming the industry growth of 1.8% [6]

Core Insights - Urban Outfitters Inc. (URBN) has demonstrated strong momentum entering the third quarter of fiscal 2026, supported by record second-quarter results and brand strength across its portfolio [1][11] - Management is confident in achieving high-single-digit total sales growth for the fiscal third quarter and maintaining solid progress for the remainder of the fiscal year [1] Retail Segment Performance - Comparable sales in the Retail segment are expected to rise in the mid-single-digit range, driven by growth at Anthropologie, Free People, and Urban Outfitters [2] - The Nuuly subscription business is forecasted to deliver mid-double-digit revenue growth, supported by continued subscriber additions [2] - The Wholesale segment is projected to post mid-single-digit revenue gains [2] Profitability and Margins - URBN anticipates that the gross profit margin for the fiscal third quarter will be flat compared to the prior year, with lower initial product margins due to higher tariffs offsetting positive impacts from reduced markdowns and improved occupancy leverage [3] - For fiscal 2026, URBN expects a gross margin improvement of 100 basis points from the prior year, with approximately 50 basis points of that improvement occurring in the second half [5][11] Expenses and Investments - Selling, general and administrative (SG&A) expenses are projected to rise slightly faster than sales, primarily due to increased marketing investments for Nuuly and Anthropologie, as well as a pre-holiday promotional push [4] - SG&A expenses for the year are anticipated to grow in line with sales, driven by marketing and labor costs associated with brand expansion and store openings [6] - Capital expenditure is planned at $270 million, with allocations of 50% for retail store expansion, 25% for technology and logistics, and 25% for office expansion [6] Market Performance and Valuation - URBN shares have gained 32.7% year to date, contrasting with the industry's decline of 9.6% [8] - The company trades at a forward price-to-earnings ratio of 13.14X, slightly below the industry's average of 18.12X, and holds a Value Score of A [9] Earnings Estimates - The Zacks Consensus Estimate for URBN's fiscal 2026 earnings implies year-over-year growth of 29.1%, with an 8.7% uptick projected for fiscal 2027 [12] - Estimates for fiscal 2026 and 2027 have been revised upward by 6 cents and 11 cents, respectively, in the past 30 days [12]

Financial Data and Key Metrics Changes - The company reported a record quarterly revenue of $6.2 million for Q4 2025, up from $4.2 million in the previous quarter and $4.7 million in Q4 2024, leading to an annualized run rate of approximately $25 million [5][22] - For the fiscal year 2025, total revenue was flat at $19.1 million compared to the prior year, masking the transition from an engineering-focused business to a manufacturing enterprise [22][24] - Gross margins for Q4 2025 were 13%, compared to 10% in the prior quarter and 22% in Q4 2024, with annual gross margins at 18%, down from 30% in the previous year [24][27] Business Line Data and Key Metrics Changes - Production revenue reached $5.1 million in Q4 2025, up from $3.3 million in the prior quarter and $2.8 million in the year-ago quarter, while engineering revenue decreased to $1.1 million from $1.9 million year-over-year [22][24] - The systems manufacturing business is expected to grow at least 75% in fiscal 2026, driven by the expansion of two major production programs [14][21] - Revenue from the micro-optics lab is projected to drop from $2.1 million in fiscal 2025 to $1.3 million in fiscal 2026 due to timing of a large defense customer reorder [24] Market Data and Key Metrics Changes - The company anticipates fiscal 2026 revenues to reach approximately $25 million, an increase of over 30% compared to $19 million in 2025, primarily driven by the systems manufacturing business [21][22] - The backlog for the aerospace program has reached nearly $9 million, indicating strong demand and future revenue potential [10] Company Strategy and Development Direction - The company is focusing on transitioning programs from development to production, with expectations of two to three programs moving to production each year over the next two years [14][15] - Investments have been made in facilities and talent to support growth, including relocating headquarters to Littleton, Massachusetts, and hiring new operational staff [7][19] - The long-term margin goal remains at 40%, with expectations of improved gross margins in fiscal 2026 due to better manufacturing yields and reduced low-margin revenue [21][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing a strong production backlog and the sustainability of higher revenue levels [29] - The company is addressing gross margin challenges and expects significant recovery in fiscal 2026, with gross margins projected at approximately 30% [21][24] - Management highlighted the importance of learning from production challenges and improving operational efficiency as the company matures [29] Other Important Information - The company has recently hired a new Chief Operating Officer with extensive experience in medical device production to enhance operational performance [20] - Tariff reimbursement agreements are in progress, which are expected to positively impact margins [18][41] Q&A Session Summary Question: Guidance on revenue for 2026 - Management acknowledged being conservative in their revenue guidance for 2026, noting a decrease in revenue from the micro-optics lab due to timing of orders [34][35] Question: Medical program pricing adjustments - The client has agreed to cover higher costs due to initial production difficulties, with a plan to ramp down prices as issues are resolved [39][40] Question: Tariff reimbursements - Management confirmed verbal agreements on tariff reimbursements, with documentation pending [41][42] Question: Engineering resources and project pipeline - Engineering resources are expected to be progressively filled throughout 2026, with several programs already lined up for development [48][49] Question: Challenges in the second single-use program - The second single-use program is progressing well, with lessons learned from the cystoscope program aiding in smoother ramp-up [61][63]

Core Viewpoint - Chanson International Holding demonstrated resilience in the first half of fiscal year 2025, achieving revenue growth despite market challenges, while maintaining gross margins above 40% through cost control and operational efficiency [2][4]. Financial Summary - Total revenue for the six months ended June 30, 2025, was $8.7 million, a 15.2% increase from $7.5 million in the same period last year [4][6]. - Gross profit increased to $3.9 million, up 23.6% from $3.1 million year-over-year, with a gross margin of 44.5%, compared to 41.5% previously [6][10]. - The company reported a net loss of $1.0 million, contrasting with a net income of $0.02 million for the same period last year [15][16]. Revenue Breakdown - Revenue from China Stores reached $7.8 million, a 19.7% increase from $6.5 million, primarily driven by bakery products [5][4]. - Revenue from U.S. Stores was $0.9 million, down 13.2% from $1.0 million, mainly due to decreased bakery product sales [9][4]. Product Performance - Bakery products generated $7.2 million in revenue, a 20.8% increase from $5.9 million, attributed to new store openings [7][4]. - Revenue from seasonal products rose by 39.0% to $0.51 million, while beverage product revenue fell by 42.9% to $0.12 million due to increased competition [8][7]. Operating Expenses - Operating expenses totaled $5.1 million, up from $3.7 million year-over-year, with selling expenses increasing by 26.3% to $2.8 million [11][13]. - General and administrative expenses rose by 53.7% to $2.2 million, largely due to increased allowances for credit losses [14][13]. Cash Position - As of June 30, 2025, the company had cash reserves of $22.1 million, significantly up from $12.1 million at the end of 2024 [17][18]. - Net cash used in operating activities was $0.4 million, compared to net cash provided of $0.8 million in the same period last year [18][18]. Company Overview - Chanson International Holding, founded in 2009, operates bakery, seasonal, and beverage product stores in China and the U.S., managing 60 stores in China and three in New York City [19].